Evidence map›Paper›PMID 35465399›Full record

ArticleNeural plasticity2022

Growth Hormone Increases BDNF and mTOR Expression in Specific Brain Regions after Photothrombotic Stroke in Mice.

Sonia Sanchez-Bezanilla, Daniel J Beard, Rebecca J Hood, N David Åberg, Patricia Crock, Frederick R Walker, Michael Nilsson, Jörgen Isgaard, Lin Kooi Ong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neural plasticity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

Sonia Sanchez-BezanillaSchool of Biomedical Sciences and Pharmacy and the Priority Research Centre for Stroke and Brain Injury, The University of Newcastle, NSW, Australia.
Daniel J BeardSchool of Biomedical Sciences and Pharmacy and the Priority Research Centre for Stroke and Brain Injury, The University of Newcastle, NSW, Australia.
Rebecca J HoodSchool of Biomedical Sciences and Pharmacy and the Priority Research Centre for Stroke and Brain Injury, The University of Newcastle, NSW, Australia.
N David ÅbergInstitute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Patricia CrockHunter Medical Research Institute, NSW, Australia.
Frederick R WalkerSchool of Biomedical Sciences and Pharmacy and the Priority Research Centre for Stroke and Brain Injury, The University of Newcastle, NSW, Australia.
Michael NilssonSchool of Biomedical Sciences and Pharmacy and the Priority Research Centre for Stroke and Brain Injury, The University of Newcastle, NSW, Australia.
Jörgen IsgaardSchool of Biomedical Sciences and Pharmacy and the Priority Research Centre for Stroke and Brain Injury, The University of Newcastle, NSW, Australia.ORCID 0000-0002-8445-6923
Lin Kooi OngSchool of Biomedical Sciences and Pharmacy and the Priority Research Centre for Stroke and Brain Injury, The University of Newcastle, NSW, Australia.ORCID 0000-0001-8664-0540
Hunter Medical Research Institute · AUSahlgrenska University Hospital · SEMonash University Malaysia · MYNanyang Technological University · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: We have shown that growth hormone (GH) treatment poststroke increases neuroplasticity in peri-infarct areas and the hippocampus, improving motor and cognitive outcomes. We aimed to explore the mechanisms of GH treatment by investigating how GH modulates pathways known to induce neuroplasticity, focusing on association between brain-derived neurotrophic factor (BDNF) and mammalian target of rapamycin (mTOR) in the peri-infarct area, hippocampus, and thalamus. Methods: Recombinant human growth hormone (r-hGH) or saline was delivered (0.25 Results: r-hGH treatment significantly increased pro-BDNF in peri-infarct area, hippocampus, and thalamus ( Conclusion: r-hGH increases pro-BDNF within the peri-infarct area and regions that are known to experience secondary neurodegeneration after stroke. Upregulation of total-mTOR protein expression in the peri-infarct and thalamus suggests that this might be a pathway that is involved in the neurorestorative effects previously reported in these animals and warrants further investigation. These findings suggest region-specific mechanisms of action of GH treatment and provide further understanding for how GH treatment promotes neurorestorative effects after stroke.

Indexed as

Human Growth HormoneStrokeAnimalsBrainBrain-Derived Neurotrophic FactorGrowth HormoneInfarctionMammalsMiceRibosomal Protein S6 Kinases, 70-kDaTOR Serine-Threonine KinasesBrain-Derived Neurotrophic FactorGrowth HormoneHuman Growth HormoneRibosomal Protein S6 Kinases, 70-kDaTOR Serine-Threonine Kinases

Identifiers

PMID35465399
PMCPMC9033347
OpenAlexW4224040865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.